491 related articles for article (PubMed ID: 24828856)
1. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
[TBL] [Abstract][Full Text] [Related]
3. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study.
Zhou Y; He H; Wang P; Zhang T; Lin M; Wang H; Nie Y; Chen Y
Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1270-5. PubMed ID: 26275085
[TBL] [Abstract][Full Text] [Related]
4. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
[TBL] [Abstract][Full Text] [Related]
5. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB
Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.
Yamada S; Yoshino T; Matsuura M; Minami N; Toyonaga T; Honzawa Y; Tsuji Y; Nakase H
BMC Gastroenterol; 2014 Apr; 14():80. PubMed ID: 24758588
[TBL] [Abstract][Full Text] [Related]
8. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
[TBL] [Abstract][Full Text] [Related]
9. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
[TBL] [Abstract][Full Text] [Related]
10. Duration of disease may predict response to infliximab in pediatric ulcerative colitis.
Mir SA; Nagy-Szakal D; Smith EO; Gilger MA; Kellermayer R
J Clin Gastroenterol; 2014 Mar; 48(3):248-52. PubMed ID: 24129407
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population.
Juliao F; Marquez J; Aristizabal N; Yepes C; Zuleta J; Gisbert JP
Digestion; 2013; 88(4):222-8. PubMed ID: 24281150
[TBL] [Abstract][Full Text] [Related]
12. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.
Vahabnezhad E; Rabizadeh S; Dubinsky MC
Inflamm Bowel Dis; 2014 Apr; 20(4):606-13. PubMed ID: 24552827
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
14. Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers.
Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
Eur J Intern Med; 2014 Oct; 25(8):757-61. PubMed ID: 25086677
[TBL] [Abstract][Full Text] [Related]
15. Histological healing after infliximab induction therapy in children with ulcerative colitis.
Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
[TBL] [Abstract][Full Text] [Related]
16. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.
Laharie D; Filippi J; Roblin X; Nancey S; Chevaux JB; Hébuterne X; Flourié B; Capdepont M; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2013 May; 37(10):998-1004. PubMed ID: 23521659
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
Nuki Y; Esaki M; Asano K; Maehata Y; Umeno J; Moriyama T; Nakamura S; Matsumoto T; Kitazono T
Scand J Gastroenterol; 2016; 51(6):700-5. PubMed ID: 26818468
[TBL] [Abstract][Full Text] [Related]
18. Does infliximab prevent colectomy in acute and chronic active ulcerative colitis?
Dan-Nielsen S; Wewer V; Paerregaard A; Hansen LF; Nielsen RG; Lange A; Jakobsen C
J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):768-72. PubMed ID: 24572593
[TBL] [Abstract][Full Text] [Related]
19. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis.
Löwenberg M; Duijvis NW; Ponsioen C; van den Brink GR; Fockens P; D'Haens GR
Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1240-6. PubMed ID: 25171024
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]